Clinical Trial · NCT02284919

[18F]ISO-1 Positron Emission Tomography (PET/CT) in Primary Breast Cancer

Overview

In this study, positron emission tomography (PET/CT) imaging will be used to evaluate sigma-2 (σ2) receptor activity in sites of primary breast cancer using the investigational radiotracer \[18F\]ISO-1.

Sponsor

University of Pennsylvania

Phase

Phase 1

Contacts

Elizabeth McDonald, MD, PhD (PRINCIPAL_INVESTIGATOR)

David Mankoff, MD, PhD (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT02284919

Drug / Compound

ISO-1

Isotope(s):

Target(s):

PARP

Ligand Class: Small Molecules

Eligibility

Inclusion

Participants must be informed of the investigational nature of this study and provide written informed consent in accordance with institutional and federal guidelines prior to study-specific procedures
1. Adult patients, at least 18 years of age
Known or suspected breast cancer with at least one breast lesion that is 1 cm or greater in size by standard imaging (e.g. mammography, ultrasound or breast MRI)

Exclusion

Serious or unstable medical or psychological conditions that, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study.
Inability to tolerate imaging procedure in the opinion of an investigator or treating physician
Unwilling or unable to provide informed consent.
1. Females who are pregnant at the time of screening will not be eligible for this study, urine or serum pregnancy test will be performed in women of child-bearing potential at the time of screening.